Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Uveitis treatment Market

Uveitis Treatment Market Size, Share & Trends Analysis Report, By Disease Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis), By Drug Class (Corticosteroids, Immunosuppressants, Biologics, Anti-infective Agents, Cycloplegic Agents), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers), Forecast Period (2026–2035)

Published: Jun 2026 | Report Code: OMR2029754 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Uveitis treatment market is valued at $1.90 billion in 2025 and is projected to reach $3.36 billion by 2035, expanding at a CAGR of 5.86% from 2026 to 2035. The market growth is primarily driven by the increasing burden of inflammatory eye diseases, rising geriatric population, and advancements in biologic therapies. According to the World Health Organization (WHO), over 2.2 billion people globally live with vision impairment, with inflammatory eye conditions such as uveitis being a significant contributor to preventable blindness. Additionally, the WHO estimates that at least 1 billion cases could have been prevented or are yet to be addressed, emphasizing the urgent need for effective treatment solutions. The increasing demand for ophthalmology services is further supported by OECD healthcare statistics, which highlight a steady rise in specialist consultations, including ophthalmology visits, particularly in aging populations across developed economies. Hospitals, ophthalmology clinics, and ambulatory surgical centers remain the primary end users, driving treatment adoption through improved diagnostic capabilities and access to advanced therapeutics.

Market Dynamics

Rising Burden of Vision Disorders Driving Market Growth

The increasing prevalence of vision impairment and ocular inflammatory diseases is a major growth driver for the uveitis treatment market. The WHO reports that vision impairment affects over 2.2 billion individuals globally, with a significant proportion linked to inflammatory and autoimmune eye conditions. Uveitis alone accounts for approximately 5–10% of blindness cases in developed countries, indicating a substantial clinical burden. Furthermore, data from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights growing investments in ophthalmology drug development, particularly biologics and targeted immunotherapies. Pharmaceutical companies are actively focusing on expanding treatment pipelines, improving drug delivery systems, and enhancing long-term disease management outcomes. Companies are emphasizing biologic therapies and sustained-release implants, which offer improved efficacy and patient compliance compared to conventional corticosteroids. Increasing awareness campaigns, early diagnosis initiatives, and government-supported eye health programs are also contributing to higher treatment adoption rates globally.

High Treatment Costs and Limited Accessibility as Key Challenges

Despite significant advancements, the uveitis treatment market faces challenges related to high treatment costs and limited accessibility in low- and middle-income countries. Biologic therapies, while effective, are often expensive and require long-term administration, posing affordability issues for patients. According to OECD healthcare expenditure data, rising healthcare costs are placing pressure on reimbursement systems, particularly for specialty treatments such as biologics. Additionally, access to specialized ophthalmology care remains uneven, especially in rural and underserved regions.

Supply chain disruptions and regulatory complexities also impact drug availability. The U.S. Food and Drug Administration (FDA) emphasizes stringent approval processes for ophthalmic drugs, which can delay product commercialization. However, companies are addressing these challenges through biosimilar development, cost-effective manufacturing, and strategic partnerships to improve market penetration and accessibility.

Market Segmentation

  • Based on the Disease Type, the market is segmented into Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, and Panuveitis.
  • Based on the Drug Class, the market is segmented into Corticosteroids, Immunosuppressants, Biologics, Anti-infective Agents, and Cycloplegic Agents.
  • Based on the End User, the market is segmented into Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers (ASCs).

Corticosteroids Segment Leads the Market

Corticosteroids dominate the uveitis treatment market due to their widespread use as first-line therapy for inflammation control. These drugs are extensively prescribed across hospitals and ophthalmology clinics for both acute and chronic uveitis cases. The high adoption rate is supported by their rapid anti-inflammatory action, cost-effectiveness, and availability in multiple formulations, including eye drops, injections, and implants. Between 2022 and 2026, leading pharmaceutical companies have focused on enhancing corticosteroid formulations to improve patient compliance and reduce side effects. Additionally, regulatory approvals for advanced steroid-based implants have strengthened this segment’s market position. Increasing patient inflow in ophthalmology centers and rising awareness about early treatment further support the dominance of corticosteroids.

Biologics Segment to Record Strong Growth

The biologics segment is expected to witness the fastest growth during the forecast period due to advancements in targeted therapies and increasing adoption of monoclonal antibodies. Biologics offer superior efficacy in treating chronic and non-infectious uveitis, particularly in patients unresponsive to conventional therapies. Innovations in immunomodulatory drugs and biosimilars are driving market expansion. Investment in R&D and clinical trials has significantly increased, with companies focusing on developing next-generation biologics. The growing approval of biosimilars is also improving treatment affordability, accelerating adoption across emerging markets.

Regional Outlook

The global uveitis treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the uveitis treatment market due to advanced healthcare infrastructure and high adoption of innovative therapies. According to the Centers for Disease Control and Prevention (CDC), millions of Americans are affected by vision-related disorders annually, driving demand for ophthalmology treatments. The presence of leading pharmaceutical companies, strong regulatory support from the FDA, and increasing healthcare expenditure contribute to market growth. Additionally, rising awareness and early diagnosis initiatives are further boosting treatment adoption.

India to Record Strong Growth

India is expected to witness rapid growth due to increasing healthcare investments and rising prevalence of eye disorders. According to the WHO, India has a significant burden of preventable blindness, creating strong demand for affordable treatment solutions. Government initiatives such as national eye health programs and expanding healthcare infrastructure are supporting market growth. Additionally, the presence of generic drug manufacturers and increasing access to ophthalmology services are driving treatment adoption across urban and rural regions.

Competitive Landscape

The global uveitis treatment market is highly competitive, characterized by the presence of major pharmaceutical and biotechnology companies focusing on innovation and strategic collaborations. Companies such as AbbVie Inc., Bausch + Lomb (Bausch Health), Alimera Sciences, EyePoint Pharmaceuticals, and Allergan (AbbVie) are actively investing in R&D, product development, and geographic expansion to strengthen their market position. The competitive landscape is shaped by advancements in biologics, sustained drug delivery systems, and biosimilars, along with efforts to improve accessibility and affordability.

Recent Developments

  • In March 2025, ANI Pharmaceuticals received U.S. FDA approval for an expanded label of ILUVIEN to include chronic non-infectious uveitis affecting the posterior segment of the eye.
    The therapy, previously approved for diabetic macular edema, is a corticosteroid intravitreal implant designed for long-term inflammation control. The company plans to commercialize ILUVIEN in the U.S. under the expanded indication.
  • In June 2025, Amneal Pharmaceuticals received U.S. FDA approval for prednisolone acetate ophthalmic suspension, 1% for treating steroid-responsive ocular inflammation.
    The product is a topical corticosteroid widely used in managing inflammatory eye conditions.
    Commercial launch is planned for the third quarter of 2025.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global uveitis treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Uveitis Treatment Market Sales Analysis – Disease Type | Drug Class | End User ($ Million)
  • Uveitis Treatment Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Uveitis Treatment Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Uveitis Treatment Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Uveitis Treatment Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Uveitis Treatment Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Uveitis Treatment Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Uveitis Treatment Market Revenue and Share by Manufacturers

  • Uveitis Treatment Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 AbbVie Inc.

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Bausch + Lomb (Bausch Health)

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 Alimera Sciences

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 EyePoint Pharmaceuticals

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 Allergan (AbbVie)

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. Global Uveitis Treatment Market Sales Analysis by Disease Type ($ Million)

5.1 Anterior Uveitis

5.2 Intermediate Uveitis

5.3 Posterior Uveitis

5.4 Panuveitis

  1. Global Uveitis Treatment Market Sales Analysis by Drug Class ($ Million)

6.1 Corticosteroids

6.2 Immunosuppressants

6.3 Biologics

6.4 Anti-infective Agents

6.5 Cycloplegic Agents

  1. Global Uveitis Treatment Market Sales Analysis by End User ($ Million)

7.1 Hospitals

7.2 Ophthalmology Clinics

7.3 Ambulatory Surgical Centers (ASCs)

  1. Regional Analysis

8.1 North American Uveitis Treatment Market Sales Analysis – Disease Type | Drug Class | End User ($ Million)

8.1.1 United States

8.1.2 Canada

8.2 European Uveitis Treatment Market Sales Analysis – Disease Type | Drug Class | End User ($ Million)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

8.3 Asia-Pacific Uveitis Treatment Market Sales Analysis – Disease Type | Drug Class | End User ($ Million)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Uveitis Treatment Market Sales Analysis – Disease Type | Drug Class | End User ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Akorn Operating Company LLC

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2 Amgen Inc.

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3 Aurobindo Pharma

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4 Bristol Myers Squibb

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5 Cipla Ltd.

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6 Clearside Biomedical

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7 Hikma Pharmaceuticals

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8 Hospira (Pfizer)

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.9 Johnson & Johnson (Janssen)

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.10 Lupin Limited

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies

9.11 Novartis AG

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Ocular Therapeutix, Inc.

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Pfizer Inc.

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 Regeneron Pharmaceuticals

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 Roche (Genentech)

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Sanofi S.A.

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 Santen Pharmaceutical Co., Ltd.

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies

9.18 Sun Pharmaceutical Industries

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 Tarsier Pharma

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 UCB S.A.

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Uveitis Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million) 

2. Global Anterior Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

3. Global Intermediate Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

4. Global Posterior Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

5. Global Pan Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

6. Global Uveitis Treatment Market Research and Analysis by Drug Class, 2026–2035 ($ Million) 

7. Global Corticosteroids Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

8. Global Immunosuppressants Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

9. Global Biologics Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

10. Global Anti-infective Agents Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

11. Global Cycloplegic Agents Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

12. Global Uveitis Treatment Market Research and Analysis by End User, 2026–2035 ($ Million) 

13. Global Uveitis Treatment for Hospitals Market Research and Analysis by Region, 2026–2035 ($ Million) 

14. Global Uveitis Treatment for Ophthalmology Clinics Market Research and Analysis by Region, 2026–2035 ($ Million) 

15. Global Uveitis Treatment for Ambulatory Surgical Centers Market Research and Analysis by Region, 2026–2035 ($ Million) 

16. Global Uveitis Treatment Market by Region, 2026–2035 ($ Million) 

17. North America Uveitis Treatment Market Research and Analysis by Country, 2026–2035 ($ Million) 

18. North America Uveitis Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million) 

19. North America Uveitis Treatment Market Research and Analysis by Drug Class, 2026–2035 ($ Million) 

20. North America Uveitis Treatment Market Research and Analysis by End User, 2026–2035 ($ Million) 

21. Europe Uveitis Treatment Market Research and Analysis by Country, 2026–2035 ($ Million) 

22. Europe Uveitis Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million) 

23. Europe Uveitis Treatment Market Research and Analysis by Drug Class, 2026–2035 ($ Million) 

24. Europe Uveitis Treatment Market Research and Analysis by End User, 2026–2035 ($ Million) 

25. Asia-Pacific Uveitis Treatment Market Research and Analysis by Country, 2026–2035 ($ Million) 

26. Asia-Pacific Uveitis Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million) 

27. Asia-Pacific Uveitis Treatment Market Research and Analysis by Drug Class, 2026–2035 ($ Million) 

28. Asia-Pacific Uveitis Treatment Market Research and Analysis by End User, 2026–2035 ($ Million) 

29. Rest of the World Uveitis Treatment Market Research and Analysis by Region, 2026–2035 ($ Million) 

30. Rest of the World Uveitis Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million) 

31. Rest of the World Uveitis Treatment Market Research and Analysis by Drug Class, 2026–2035 ($ Million) 

32. Rest of the World Uveitis Treatment Market Research and Analysis by End User, 2026–2035 ($ Million) 

1. Global Uveitis Treatment Market Share by Disease Type, 2025 Vs 2035 (%) 

2. Global Anterior Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

3. Global Intermediate Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

4. Global Posterior Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

5. Global Pan Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

6. Global Uveitis Treatment Market Share by Drug Class, 2025 Vs 2035 (%) 

7. Global Corticosteroids Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

8. Global Immunosuppressants Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

9. Global Biologics Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

10. Global Anti-infective Agents Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

11. Global Cycloplegic Agents Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

12. Global Uveitis Treatment Market Share by End User, 2025 Vs 2035 (%) 

13. Global Uveitis Treatment for Hospitals Market Share by Region, 2025 Vs 2035 (%) 

14. Global Uveitis Treatment for Ophthalmology Clinics Market Share by Region, 2025 Vs 2035 (%) 

15. Global Uveitis Treatment for Ambulatory Surgical Centers Market Share by Region, 2025 Vs 2035 (%) 

16. Global Uveitis Treatment Market Share by Region, 2025 Vs 2035 (%) 

17. United States Uveitis Treatment Market Size, 2025–2035 ($ Million) 

18. Canada Uveitis Treatment Market Size, 2025–2035 ($ Million) 

19. UK Uveitis Treatment Market Size, 2025–2035 ($ Million) 

20. France Uveitis Treatment Market Size, 2025–2035 ($ Million) 

21. Germany Uveitis Treatment Market Size, 2025–2035 ($ Million) 

22. Italy Uveitis Treatment Market Size, 2025–2035 ($ Million) 

23. Spain Uveitis Treatment Market Size, 2025–2035 ($ Million) 

24. Russia Uveitis Treatment Market Size, 2025–2035 ($ Million) 

25. India Uveitis Treatment Market Size, 2025–2035 ($ Million) 

26. China Uveitis Treatment Market Size, 2025–2035 ($ Million) 

27. Japan Uveitis Treatment Market Size, 2025–2035 ($ Million) 

28. South Korea Uveitis Treatment Market Size, 2025–2035 ($ Million) 

29. Australia & New Zealand Uveitis Treatment Market Size, 2025–2035 ($ Million) 

30. ASEAN Uveitis Treatment Market Size, 2025–2035 ($ Million) 

31. Rest of Asia-Pacific Uveitis Treatment Market Size, 2025–2035 ($ Million) 

32. Latin America Uveitis Treatment Market Size, 2025–2035 ($ Million) 

33. Middle East & Africa Uveitis Treatment Market Size, 2025–2035 ($ Million) 

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The market is valued at $1.90 billion in 2025 and is projected to reach $3.36 billion by 2035.
The market is expected to grow at a CAGR of 5.86% during 2026–2035.
The corticosteroids segment dominates due to its widespread use as first-line therapy.
North America, particularly the United States, leads due to advanced healthcare infrastructure.
Biologics is the fastest-growing segment due to innovation and targeted therapies.